Travere Therapeutics Inc.

TVTX | NASDAQ

Price Alert Chart Builder DCF Calculator

$62.86

+$0.10 (+0.16%)

At close: Sep 21, 2026, 4:00 PM ET

$61.79

-$1.07 (-1.70%)

Pre-market: Sep 22, 2026, 4:20 AM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

Market Data

Market Cap $5.84B

Enterprise Value $5.97B

Beta 1.06

Average Volume 1.93M

Shares Outstanding (Diluted) 93.48M

Shares Change YoY 5.1%

Institutional Ownership N/A

Exchange NASDAQ

ISIN US89422G1076

Price Performance

Price Change 1M -4.0%

Price Change 3M 12.3%

Price Change 6M 128.1%

Price Change YTD 59.1%

Price Change 1Y 147.2%

Price Change 3Y 700.8%

Price Change 5Y 155.2%

1M CAGR (ann.) 0.5%

1Y CAGR (ann.) 165.4%

5Y CAGR (ann.) 21.7%

All-Time CAGR 30.9%

Valuation

PE Ratio -128.29

Forward PE 9.98

PEG Ratio 1.22

Forward PEG 0.01

PS Ratio 9.89

Forward PS 5.40

PB Ratio 238.38

P/FCF Ratio 524.17

P/Adj. FCF Ratio -89.03

P/OCF Ratio 63.49

EV/Sales 10.10

EV/EBIT -103.72

EV/EBITDA 3,868.69

EV/FCF 535.62

Earnings Yield -0.8%

FCF Yield 0.2%

Adj. FCF Yield -1.1%

Financial Health

Net Debt $119.77M

Total Debt $616.91M

Cash & Short-Term Investments $489.18M

Total Assets $799.36M

Current Ratio 4.05

Quick Ratio 3.99

Debt / Equity Ratio 25.16

Debt / EBITDA 399.55

Debt / FCF 55.32

OCF / Debt 0.08

Interest Coverage -4.27

Altman Z-Score 3.01

Piotroski F-Score 5

Margins & Profitability

Gross Profit Margin 94.4%

Operating Profit Margin -6.8%

EBITDA Margin 0.3%

Net Profit Margin -7.3%

FCF Margin 1.9%

Adj. FCF Margin -11.1%

SBC / Revenue 10.3%

SBC Impact (per share) -688.7%

Returns

Return on Assets -5.4%

Return on Equity -55.8%

Return on Invested Capital -6.2%

Return on Capital Employed -6.3%

Return on Tangible Assets -6.5%

Historical Growth (CAGR)

Revenue CAGR 3Y 50.6%

Revenue CAGR 5Y 23.7%

Revenue CAGR 10Y 17.2%

EPS CAGR 3Y 88.5%

EPS CAGR 5Y 28.4%

EPS CAGR 10Y -0.5%

FCF CAGR 3Y 108.8%

FCF CAGR 5Y 21.2%

FCF CAGR 10Y -12.7%

Analyst Forecasts

Analyst Rating Buy

Analyst Count 18

EPS Growth Next 3Y 377.8%

Revenue Growth Next 3Y 39.4%

Earnings Date Oct 28, 2026

EPS Estimate (next Q) $0.05

EPS Growth Est (next Q) -82.1%

Revenue Est (next Q) $195.68M

Revenue Growth Est (next Q) 18.7%

Fair Value Estimates

Graham Number N/A

Graham Upside N/A

Lynch Fair Value N/A

Lynch Upside N/A

Price Target $65.80

Price Target Upside 4.7%

Cash Flow

Operating Cash Flow $52.33M

Free Cash Flow $11.15M

Adj. Free Cash Flow $-65.66M

FCF Per Share $0.55

OCF Per Share $0.99

OCF/S Ratio 15.7%

Income Statement

Revenue $591.33M

Gross Profit $558.25M

Operating Income $-40.46M

EBITDA $1.54M

Net Income $-43.46M

EPS (Diluted) -$0.49

Revenue / Employee $1.19M

Profit / Employee $-87.45K

Employees 497